ClinicalTrials.gg
CompletedNCT04555616Updated Apr 12, 2023Results posted

Environmental Design for Behavioral Regulation in People With Dementia

An interventional study of Standard Environmental Design and Individual Environmental Design in Alzheimer Disease, sponsored by Elizabeth K Rhodus. Completed at 1 site in United States. Open to participants aged 21 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-12.

Sponsored by Elizabeth K Rhodus · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
21 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,941 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 444 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
1,147th of 1,610
30 · median 73
Started
2021
with 144 others
No phase
610 of 1,941
131 open now
Registered
1,244th of 1,941
by date

Among the 1,941 studies in Alzheimer Disease with a site in United States, this one is the 1,147th largest by enrollment of the 1,610 interventional ones that give a count, is one of 145 that started in 2021, is one of 610 with no phase, and was the 1,244th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,941 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 21 Years to 90 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,941 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

Individuals with dementia present with changes in behaviors throughout the continuum of cognitive decline. Environmental features may be influential in behavioral regulation. The purpose of this study is to assess the feasibility of environmental design protocols in older adults with dementia and their caregivers. Thirty subjects with moderate to severe Alzheimer's disease as primary dementia type, and their caregivers, will be randomly assigned to one of three arms: standard care; standard environmental design protocol; or personalized environmental design protocol.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

Keywords

  • environment
  • Occupational therapy
04

Who can participate

Ages eligible
21 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women aged 21-90, inclusive.
  • Living at home in the community with one primary caregiver.
  • Diagnosis of Alzheimer's disease as primary dementia type of moderate to severe stages
  • Stable medical condition for one month prior to screening visit
  • Stable medications for 4 weeks prior to screening visit
  • Caregiver report of challenges related to behaviors within 4 weeks of study enrollment
  • Caregiver willing to participant throughout duration of study

Exclusion criteria

Exclusion Criteria:

  • Unstable medical conditions for 3 months prior to screening
  • Wheelchair or bed bound.
  • Residence in skilled nursing facility or facility-based care.
  • Skin lesions or skin abnormalities throughout upper extremities.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Placebo comparator
    Control Group

    Alzheimer's disease patients and caregivers.

    Behavioral: Placebo

  • Experimental
    Standard Environmental Design

    Alzheimer's disease patients and caregivers.

    Behavioral: Standard Environmental Design

  • Experimental
    Individualized Environmental Design Protocol

    Alzheimer's disease patients and caregivers.

    Behavioral: Individual Environmental Design

Interventions

  • BehavioralStandard Environmental Design

    Participants' caregivers will receive set script of physical environmental modifications (i.e., declutter living space, reduce background noise, increase natural light), and social environment training script will include caregiving techniques: training for calming demeanor (emotional contagion), needs-driven care to decrease behavioral disruption, and accepting and accommodating approach to behavioral disruption. A pre-selected sensory stimulation kit will be provided to each participants' caregiver for administration throughout the day.

  • BehavioralIndividual Environmental Design

    Participants' caregivers will receive set script of physical environmental modifications and social environment training script in a standard protocol. Following initial assessments, individualized sensory stimulation kits will be developed using subjects' preferred sensory stimuli (as determined by the Adult Sensory Profile assessment and informant report) and will be provided via caregiver administration throughout the day to promote maintained behavioral regulation.

  • BehavioralPlacebo

    Participants' caregivers will receive a set script of placebo modifications.

06

What researchers measure

Primary outcomes

  1. Success Rate of Adherence

    Percentage of participants who had 75% adherence to the protocol based on visits and journals.

    Time frame: 6 weeks

Secondary outcomes

  1. Change in Occupational Performance

    Occupational performance will be measured using the Canadian Occupational Performance Measure (COPM) at baseline, post-intervention and the 4-week follow up. Scores range from 0-10; higher scores indicate (increased) occupational performance.

    Time frame: 10 weeks (at baseline, 6 weeks and the 4 week follow up)

  2. Change in Behavior

    Behavior will be measured using the Neuropsychiatric Inventory (NPI-Q) at baseline, post-intervention and the 4-week follow up. Scores range from 1-36; higher scores indicate higher behavior severity.

    Time frame: 10 weeks (at baseline, 6 weeks and the 4 week follow up)

07

Results

Posted Apr 12, 2023

Participant flow

Individuals diagnosed with Alzheimer's disease (Clinical Dementia Rating Scale \[CDR\] score of 1.0+) living in the community with caregiver-identified behavioral disturbance were recruited from the UK Alzheimer's Disease Research Center (UK ADRC)

Participant flow — Overall Study
MilestoneControl GroupStandard Environmental DesignIndividualized Environmental Design Protocol
Started101010
Completed799
Not completed311
Withdrew: Death101
Withdrew: Withdrawal by subject210

Outcome measures

PrimarySuccess Rate of Adherence

Percentage of participants who had 75% adherence to the protocol based on visits and journals.

Time frame:
6 weeks
Reported as:
Count of participants · Participants
Success Rate of Adherence
ParticipantsControl GroupStandard Environmental DesignIndividualized Environmental Design Protocol
Success Rate of Adherence267
Statistical analysis
  • Control Group vs Standard Environmental Design vs Individualized Environmental Design Protocol · Fisher Exact · p = 0.12
SecondaryChange in Occupational Performance

Occupational performance will be measured using the Canadian Occupational Performance Measure (COPM) at baseline, post-intervention and the 4-week follow up. Scores range from 0-10; higher scores indicate (increased) occupational performance.

Time frame:
10 weeks (at baseline, 6 weeks and the 4 week follow up)
Reported as:
Mean · score on a scale
Change in Occupational Performance
score on a scaleControl GroupStandard Environmental DesignIndividualized Environmental Design Protocol
Baseline4.6 ± 0.43.6 ± 0.84.4 ± 0.8
Post Intervention4.6 ± 1.66.1 ± 1.16.6 ± 0.9
4-week follow up5 ± 1.45.2 ± 2.66.4 ± 2.6
SecondaryChange in Behavior

Behavior will be measured using the Neuropsychiatric Inventory (NPI-Q) at baseline, post-intervention and the 4-week follow up. Scores range from 1-36; higher scores indicate higher behavior severity.

Time frame:
10 weeks (at baseline, 6 weeks and the 4 week follow up)
Reported as:
Mean · score on a scale
Change in Behavior
score on a scaleControl GroupStandard Environmental DesignIndividualized Environmental Design Protocol
Baseline13.3 ± 2.39.8 ± 2.810.3 ± 1.7
Post-Intervention8.9 ± 2.510.8 ± 1.98.4 ± 1.7
4-week follow up5.4 ± 2.75.5 ± 3.05.8 ± 3.7

Adverse events

Collected over 10 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Control Group1/10 (10%)0/10 (0%)0/10 (0%)
Standard Environmental Design0/10 (0%)0/10 (0%)0/10 (0%)
Individualized Environmental Design Protocol1/10 (10%)0/10 (0%)0/10 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Control GroupStandard Environmental DesignIndividualized Environmental Design ProtocolTotal
PLWD77.2 ± 7.484.3 ± 5.473.3 ± 7.177.9 ± 7.9
Caregiver69.5 ± 14.067.7 ± 11.669.7 ± 11.769.0 ± 11.7
Sex: Female, Male
Sex: Female, Male(Participants)Control GroupStandard Environmental DesignIndividualized Environmental Design ProtocolTotal
PLWD — Female67821
PLWD — Male4329
Caregiver — Female98219
Caregiver — Male12811
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Control GroupStandard Environmental DesignIndividualized Environmental Design ProtocolTotal
PLWD — American Indian or Alaska Native0000
PLWD — Asian0000
PLWD — Native Hawaiian or Other Pacific Islander0000
PLWD — Black or African American1001
PLWD — White9101029
PLWD — More than one race0000
PLWD — Unknown or Not Reported0000
Caregiver — American Indian or Alaska Native0000
Caregiver — Asian0000
Caregiver — Native Hawaiian or Other Pacific Islander0000
Caregiver — Black or African American1001
Caregiver — White9101029
Caregiver — More than one race0000
Caregiver — Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Control GroupStandard Environmental DesignIndividualized Environmental Design ProtocolTotal
United States10101030
Education
Education(years)Control GroupStandard Environmental DesignIndividualized Environmental Design ProtocolTotal
PLWD14.7 ± 3.214.6 ± 2.115.6 ± 2.015.0 ± 2.4
Caregiver15.3 ± 2.516.3 ± 1.617.0 ± 2.416.3 ± 2.2
Length of Caregiving Relationship
Length of Caregiving Relationship(years)Control GroupStandard Environmental DesignIndividualized Environmental Design ProtocolTotal
Mean3.7 ± 3.53.3 ± 2.95.6 ± 3.94.4 ± 3.5
08

Study locations

1 site
  • University of Kentcuky
    Lexington, Kentucky 40536, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Oct 2021, 8 months.

Results were first posted in Apr 2023, 1 year 5 months after primary completion.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's 8 months is below that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2020
First posted
Sep 21, 2020
StartActual
Jan 25, 2021
Primary completionActual
Oct 13, 2021
CompletionActual
Oct 13, 2021
Results first posted
Apr 12, 2023
Last update
Apr 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04555616
Lead sponsor
Elizabeth K Rhodus
Responsible party
Elizabeth K Rhodus (Assistant Professor, University of Kentucky) — Sponsor-investigator
First posted
Sep 21, 2020
Start date
Jan 25, 2021
Primary completion
Oct 13, 2021
Completion
Oct 13, 2021
Results posted
Apr 12, 2023
Last update
Apr 12, 2023

Study contacts

Gregory Jicha, MD-PhD
study director · University of Kentucky

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion